Social and Non-Profit
Jobs and Labor
Oil and Gas
Fishing and Aquaculture
Metals and Mining
Pharmaceuticals and Biotechnology
Professional and Business Services
Forestry and Wood Industry
Books and Literature
Radio and Television
Home and Garden
Fashion and Luxury
Clothing and Textile
Travel and Hospitality
Boating and Yachting
Skiing and Winter Sports
The security settings of your browser are blocking the execution of scripts.
If you have changed your browser's security settings, you can click here.
News > Science
Amicus Therapeutics Inc.
Amicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in the United Kingdom
Ampio Pharmaceuticals Inc.
Ampio Receives Guidance from the FDA and Proposes a Path for Approval for Single-Injection Ampion™ for the Treatment of Pain Due to Severe Osteoarthritis of the Knee February 27, 2017
Exelixis Announces Clinical Trial Collaboration with Roche to Evaluate Cabozantinib and Atezolizumab in Locally Advanced or Metastatic Solid Tumors
Regeneron Pharmaceuticals Inc.
Regeneron and Sanofi to Present New Data on DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses
GUMC - Georgetown University Medical Center
Georgetown Announces Phase II Clinical Trial of Nilotinib for Parkinson’s Disease
Fulgent Genetics Inc.
Fulgent Genetics to Participate in 2017 BTIG Medical Technology, Life Science and Diagnostic Tools Conference
Syros Pharmaceuticals Inc.
Syros Reports Discovery of Novel Genomics Based Approach to Stratifying Patients with Acute Myeloid Leukemia at Cold Spring Harbor Conference
Aclaris Therapeutics Inc.
Aclaris Therapeutics Submits New Drug Application for A-101 as a Novel Treatment for Seborrheic Keratosis – a Common Skin Condition
Catalyst Pharmaceutical Partners Inc.
Catalyst Pharmaceuticals Supports Rare Disease Day® and Joins Global Movement to Raise Important Awareness for Rare Diseases
Clearside Biomedical Inc.
Clearside Biomedical, Inc. Redirects Pre-Clinical AMD Research Resources Toward Ongoing DME Clinical Development Program
Copyright ©2006-2017 Public Technologies Inc. |